Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

Background Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Allele 516 G>T (Gln172His) is associated with diminished activity of this isoenzyme, and may lead to differences in drug exposure. Methods We evaluated this allele as a pharmacogenetic marker of EFV and NVP pharmacokinetics and EFV toxicity in 167 participants receiving EFV and 59 receiving NVP recruited within the genetics project of the Swiss HIV Cohort Study. Drug concentrations were measured in plasma and in peripheral blood mononuclear cells (PBMCs) from the same sample. Neuropsychological toxicity of EFV (sleep disorders, mood disorders, fatigue) was assessed using a standardized questionnaire. Results and conclusions CYP2B6 516TT was associated with greater plasma and intracellular exposure to EFV, and greater plasma exposure to NVP. Intracellular drug concentration, and CYP2B6 genotype were predictors of EFV neuropsychological toxicity. CYP2B6 genotyping may be useful to complement an individualization strategy based on plasma drug determinations to increase the safety and tolerability of EFV.

[1]  S. Bandiera,et al.  Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[2]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[3]  H. Jinno,et al.  Functional characterization of cytochrome P450 2B6 allelic variants. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[4]  D. Waxman,et al.  Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[5]  P. Beaune,et al.  Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.

[6]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[7]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[8]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[9]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[10]  R H Levy,et al.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[11]  T. Uchida,et al.  Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver , 2004, Cancer science.

[12]  S. Oka,et al.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and biophysical research communications.

[13]  U. Yasar,et al.  Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.

[14]  J. Reynes,et al.  Long‐term assessment of neuropsychiatric adverse reactions associated with efavirenz , 2003, HIV medicine.

[15]  Jacques Fellay,et al.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.

[16]  T. Kamataki,et al.  A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. , 2001, Biochemical and biophysical research communications.

[17]  U. Gundert-Remy,et al.  Immunochemical analysis of cytochrome P450 variability in human leukapheresed samples and its consequences for the risk assessment process. , 2003, Regulatory toxicology and pharmacology : RTP.